Binimetinib

Binimetinib is a member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole that is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib. It is grouped under the following drug class(es): Kinase inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Mektovi, 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1 and 3-benzodiazole-6-carboxamide. Its PubChem CID is 10288191.

CAS No 606143-89-9
Molecular Formula C17H15BrF2N4O3
Molecular Weight 441.2 g/mol
Synonyms 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

Frequently Asked Questions